Articles citing this paper
A brief history of economic evaluation for human papillomavirus vaccination policy
Philippe Beutels A B D and Mark Jit C
+ Author Affiliations
- Author Affiliations
A Present address: Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp 2610, Belgium.
B School of Public Health, University of Sydney, Sydney, NSW 2006, Australia.
C Modelling and Economics Unit, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
D Corresponding author. Email: philippe.beutels@ua.ac.be
Sexual Health 7(3) 352-358 https://doi.org/10.1071/SH10018
Submitted: 16 February 2010 Accepted: 28 May 2010 Published: 19 August 2010
18 articles found in Crossref database.
Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine
Brotherton Julia M. L.,
Fairley Christopher K.,
Garland Suzanne M.,
Gertig Dorota, Saville Marion
Sexual Health. 2010 7(3). p.397
Value for money from HPV vaccination and cervical screening
Ashton Toni, Sopina Elizaveta
Human Vaccines & Immunotherapeutics. 2012 8(6). p.828
Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus
Korostil Igor A.,
Peters Gareth W.,
Cornebise Julien, Regan David G.
Statistics in Medicine. 2013 32(11). p.1917
Economic Impact of Human Papillomavirus–Associated Head and Neck Cancers in the United States
Coughlan Diarmuid, Frick Kevin D.
Otolaryngologic Clinics of North America. 2012 45(4). p.899
Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical model
Choi Yoon Hong,
Chapman Ruth,
Gay Nigel, Jit Mark
Vaccine. 2012 30(23). p.3383
The Sexual Ethics of HPV Vaccination for Boys
Luyten Jeroen,
Engelen Bart, Beutels Philippe
HEC Forum. 2014 26(1). p.27
Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries
Simonella Leonardo, Canfell Karen
Vaccine. 2015 33(1). p.34
Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal
Hutubessy Raymond,
Henao Ana Maria,
Namgyal Pem,
Moorthy Vasee, Hombach Joachim
BMC Medicine. 2011 9(1).
Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
Jit Mark, Hutubessy Raymond
Applied Health Economics and Health Policy. 2016 14(3). p.245
Development and Impact of Human Papillomavirus Vaccines
DARUS CHRISTOPHER J., MUELLER JENNIFER J.
Clinical Obstetrics & Gynecology. 2013 56(1). p.10
Mind the gaps: What's missing from current economic evaluations of universal HPV vaccination?
Marsh Kevin,
Chapman Ruth,
Baggaley Rebecca F.,
Largeron Nathalie, Bresse Xavier
Vaccine. 2014 32(30). p.3732
Improving accountability in vaccine decision-making
Timmis James Kenneth,
Black Steven, Rappuoli Rino
Expert Review of Vaccines. 2017 16(11). p.1057
Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact
Brotherton Julia ML, Gertig Dorota M
Expert Review of Anti-infective Therapy. 2011 9(8). p.627
Conceptual frameworks and key dimensions to support coverage decisions for vaccines
González-Lorenzo Marien,
Piatti Alessandra,
Coppola Liliana,
Gramegna Maria,
Demicheli Vittorio,
Melegaro Alessia,
Tirani Marcello,
Parmelli Elena,
Auxilia Francesco, Moja Lorenzo
Vaccine. 2015 33(9). p.1206
Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
Jit Mark,
Demarteau Nadia,
Elbasha Elamin,
Ginsberg Gary,
Kim Jane,
Praditsitthikorn Naiyana,
Sinanovic Edina, Hutubessy Raymond
BMC Medicine. 2011 9(1).
Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium)
Lefevere Eva,
Hens Niel,
Theeten Heidi,
Van den Bosch Karel,
Beutels Philippe,
De Smet Frank, Van Damme Pierre
Vaccine. 2011 29(46). p.8390
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges
Poljak M.
Clinical Microbiology and Infection. 2012 18 p.64
Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases
Bosch F. Xavier,
Tsu Vivien,
Vorsters Alex,
Van Damme Pierre, Kane Mark A.
Vaccine. 2012 30 p.F1
